Drug-delivery endovascular stent and method for treating restenosis
First Claim
1. An endovascular stent for placement at a vascular injury site, for inhibiting restenosis at the site, comprisinga body formed of one or more filaments, carried on the one or more filaments, a bioerodable drug-release coating having a thickness of between 3-20 microns, and composed of (i) 20-60 weight percent poly-dl-lactide polymer substrate and (ii) 40-80 weight percent of macrocyclic triene immunosuppressive compound, and a polymer undercoat having a thickness of between 1-5 microns, disposed between the stent-body filaments and said coating, said stent being expandable from a contracted condition in which the stent can be delivered to a vascular injury site via a catheter, and an expanded condition in which the stent coating can be placed in contact with the vessel at the injury site, said coating being effective to release a restenosis-inhibiting amount of the compound over a period of at least 4 weeks after the stent is placed at the vascular injury site.
3 Assignments
0 Petitions
Accused Products
Abstract
An intravascular stent and method for inhibiting restenosis, following vascular injury, is disclosed. The stent has an expandable, linked-filament body and a drug-release coating formed on the stent-body filaments, for contacting the vessel injury site when the stent is placed in-situ in an expanded condition. The coating releases, for a period of at least 4 weeks, a restenosis-inhibiting amount of a monocyclic triene immunosuppressive compound having an alkyl group substituent at carbon position 40 in the compound. The stent, when used to treat a vascular injury, gives good protection against clinical restenosis, even when the extent of vascular injury involves vessel overstretching by more than 30% diameter. Also disclosed is a stent having a drug-release coating composed of (i) 10 and 60 weight percent poly-dl-lactide polymer substrate and (ii) 40-90 weight percent of an anti-restenosis compound, and a polymer undercoat having a thickness of between 1-5 microns.
308 Citations
22 Claims
-
1. An endovascular stent for placement at a vascular injury site, for inhibiting restenosis at the site, comprising
a body formed of one or more filaments, carried on the one or more filaments, a bioerodable drug-release coating having a thickness of between 3-20 microns, and composed of (i) 20-60 weight percent poly-dl-lactide polymer substrate and (ii) 40-80 weight percent of macrocyclic triene immunosuppressive compound, and a polymer undercoat having a thickness of between 1-5 microns, disposed between the stent-body filaments and said coating, said stent being expandable from a contracted condition in which the stent can be delivered to a vascular injury site via a catheter, and an expanded condition in which the stent coating can be placed in contact with the vessel at the injury site, said coating being effective to release a restenosis-inhibiting amount of the compound over a period of at least 4 weeks after the stent is placed at the vascular injury site.
-
6. A method for inhibiting restenosis at an in vascular injury site, comprising
delivering to the vascular injury site, an endovascular stent comprising (a) a body formed of one or more filaments, (b) carried on the one or more filament(s), a bioerodable drug-release coating having a thickness of between 3-20 microns, and composed of (i) 20 to 60 weight percent poly-dl-lactide polymer substrate and (ii) 40-80 weight percent of macrocyclic triene immunosuppressive compound, and (c) a polymer undercoat having a thickness of between 1-5 microns, disposed between the stent-body filaments and said coating, and expanding the stent at the vascular injury site, to bring the stent coating in contact with the vessel at the injury site, wherein said coating is effective to release a restenosis-inhibiting amount of the compound over a period of at least 4 weeks, thus to inhibit restenosis at the site.
-
12. An endovascular stent for placement at a vascular injury site, for inhibiting restenosis at the site, comprising
a body having an open-lattice structure formed of linked filaments, and carried on the one or more filaments, a drug-release coating having a thickness of between 3-30 microns, and composed of (i) 20 to 70 weight percent polymer substrate and (ii) 30-80 weight percent macrocyclic triene immunosuppressive compound having the form: -
where R is CH2−
—
X—
OH, and X is a linear alkyl group containing 1 to 7 carbon atoms,said stent being expandable from a contracted condition in which the stent can be delivered to a vascular injury site via catheter, and an expanded condition in which the stent coating can be placed in contact with the vessel at the injury site, said coating being effective to release said a restenosis-inhibiting amount of the compound over a period of at least 4 weeks after the stent is placed at the vascular injury site. - View Dependent Claims (13, 14, 15, 16, 17, 18, 19, 20, 21)
-
-
22. An endovascular stent for placement at a vascular injury site, for inhibiting restenosis at the site, comprising
a body having an open-lattice structure formed of linked filaments, and carried on the stent-body filaments, a drug-release coating having a thickness 3-30 microns, said coating containing a mixture of polymer and a macrocyclic triene immunosuppressive compound effective for the control of restenosis, wherein said monocyclic triene immunosuppressive is present in a macrocyclic triene immunosuppressive-to-polymer ratio of greater than 50% by weight and wherein said coating is attached to said filament using a polymer underlayer of between 1-5 microns.
Specification